Mike gets people like me and the market will as well

[joeypotsandpans]

One very important note that Mike made and I can't emphasize enough was his attention on the T2 population and their disproportionate percentages with regard to Afrezza usage. He talked about Libre and Afrezza for T2 for a complete needle free experience while maintaining an instant eye on BG levels at anytime. This is so important because as a T2 it is specifically what I have been longing for. So his tweet about a huge week for diabetics he knew what it meant for us T2's more than most T2's even know right now...and he see's that the bar was lowered between Libre's approval and Afrezza's label change happening at the same time. His envisioning sales reps being able to convey this along with the increased compliance that will come with it to all those in practice whether it be Endo, Primary Care, Diabetic educators, PharmD's, insurers, etc. is why his excitement shined through in his tweet friday evening. The market hasn't even gotten it yet, but the price action is telling you they will, last week and yesterday was great for all PWD as well as those long the company and yes it has been a long time coming.

[boomboom]

Afrezza was approved ahead of its time. Our societies are trending towards wanting accurate information and results at a moments notice. It has already been proven with companies like Amazon, UberEats, and Instacart. They may not be necessary but people are willing to pay for the convenience to save personal time. Now that there are products like dexcom and libre becoming more popular to expose the inefficiencies of current insulins people will begin to want to pay more for immediate results and currently Afrezza would be leading in that department.